BioLineRx BLRX
NASDAQ BLRX
$2.32 -0.04 (-1.69%)
As of: Sep 30, 2026 · 3:52 PM EDT

BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024)

Updated

BioLineRx's Current Deferred Revenue was $2.26 million in the quarter ended Sep 30, 2024, down 58.8% from the prior quarter.

Analysis

BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024) Analysis & Trends

As of Dec 31, 2023, Current Deferred Revenue at BioLineRx came in at $12.96 million.

  • Per Business Quant data, BLRX's Current Deferred Revenue in the three quarters before the quarter ended Sep 30, 2024 was $5.48 million (quarter ended Jun 30, 2024), $9.03 million (quarter ended Mar 31, 2024) and $12.96 million (quarter ended Dec 31, 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 BioLineRx 6.16 Bn 6.16 Bn 235,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 2.26 Mn
Jun 30, 2024 5.48 Mn
Mar 31, 2024 9.03 Mn
Dec 31, 2023 12.96 Mn
API Access

BioLineRx Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BLRX&period=max&api_key=YOUR_API_KEY